Analysts expect West Pharmaceutical Services Inc. (NYSE:WST) to post $0.66 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for West Pharmaceutical Services’ earnings, with the lowest EPS estimate coming in at $0.64 and the highest estimate coming in at $0.68. West Pharmaceutical Services reported earnings of $0.62 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 6.5%. The company is expected to issue its next earnings results on Thursday, April 25th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full-year earnings of $2.85 per share for the current fiscal year, with EPS estimates ranging from $2.82 to $2.88. For the next financial year, analysts expect that the business will post earnings of $3.28 per share, with EPS estimates ranging from $3.19 to $3.35. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover West Pharmaceutical Services.
Get West Pharmaceutical Services alerts:West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, February 14th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.01. West Pharmaceutical Services had a return on equity of 16.14% and a net margin of 12.05%. The firm had revenue of $422.50 million for the quarter, compared to analysts’ expectations of $432.38 million. During the same period last year, the business posted $0.64 earnings per share. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis.
Separately, Zacks Investment Research cut West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Saturday, January 19th.
Shares of WST opened at $105.24 on Monday. West Pharmaceutical Services has a 12-month low of $82.74 and a 12-month high of $125.09. The firm has a market cap of $7.64 billion, a P/E ratio of 37.33, a PEG ratio of 3.29 and a beta of 1.22. The company has a current ratio of 2.94, a quick ratio of 2.23 and a debt-to-equity ratio of 0.15.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Wednesday, April 17th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Tuesday, April 16th. West Pharmaceutical Services’s payout ratio is 21.35%.
A number of hedge funds have recently bought and sold shares of WST. Oregon Public Employees Retirement Fund lifted its stake in West Pharmaceutical Services by 9,703.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,836,204 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 2,807,272 shares during the last quarter. Federated Investors Inc. PA lifted its stake in West Pharmaceutical Services by 3,266.9% in the third quarter. Federated Investors Inc. PA now owns 1,004,516 shares of the medical instruments supplier’s stock valued at $124,028,000 after buying an additional 974,681 shares during the last quarter. Norges Bank bought a new stake in West Pharmaceutical Services in the fourth quarter valued at $65,643,000. BlackRock Inc. lifted its stake in West Pharmaceutical Services by 4.5% in the fourth quarter. BlackRock Inc. now owns 6,939,493 shares of the medical instruments supplier’s stock valued at $680,279,000 after buying an additional 298,898 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in West Pharmaceutical Services by 386.9% in the fourth quarter. First Trust Advisors LP now owns 296,183 shares of the medical instruments supplier’s stock valued at $29,035,000 after buying an additional 235,347 shares during the last quarter. Institutional investors own 92.24% of the company’s stock.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
Read More: Moving Average (MA)
Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment